Stock 9926 AKESO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Akeso, Inc.

Equities

9926

KYG0146B1032

Delayed Hong Kong S.E.
Other stock markets
 08:23:36 14/05/2024 BST 		5-day change 1st Jan Change
49.45 HKD +0.41% Intraday chart for Akeso, Inc. +3.02% +6.68%
04-24 Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator MT
04-24 National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
AQ
Summit Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results and Operational Progress Call on February 20, 2024
AQ
Summit Therapeutics to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference
AQ
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
AQ
Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap
PR
Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naive Acute Myeloid Leukemia at ASH 2023
AQ
Akeso Launches Construction of Shanghai Global R&D Center to Accelerate Its Innovation Globalization Strategy
PR
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Met Primary Endpoint of Progression-Free Survival in Phase III Trial for First-Line Treatment of Recurrent/Metastatic Cervical Cancer in All-Comer Patients
PR
Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)
PR
Summit Therapeutics Inc. - Ivonescimab's Novel Mechanism of Action Highlighting Cooperative Binding to be featured in Poster Presentation at SITC 2023
AQ
H. Jack West, MD, Renowned Oncologist and Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical Development
AQ
Phase 1a/1b Study Results of Akeso's PD-1/CTLA-4 Bispecific Antibody Published in Cell Reports Medicine, Highlighting Promising Efficacy in Solid Tumors Refractory/Relapsed to Standard Therapy
PR
Akeso Announced Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-line PD-L1 Positive Advanced NSCLC
PR
Akeso Announced that Ivonescimab Granted Priority Review of NDA by China NMPA
PR
Akeso Announced NDA Acceptance of IL-12/lL-23 Monoclonal Antibody Ebdarokimab for Moderate-to-severe Plaque Psoriasis by China NMPA
PR
Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC
PR
Summit Therapeutics to Host Q2 2023 Financial Results and Operational Progress Call on August 9, 2023
AQ
Summit Therapeutics Inc. - Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023
AQ
Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab
AQ
Akeso Reported 2022 Annual Results
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 9926 Stock
  4. News Akeso, Inc.
  5. Press Releases